Wheeler Bio Partners with Pharmefex to Enhance ModularCMC Platform for IND Submissions
核心洞察
Wheeler Bio (搜索), a U.S.-based CDMO, has established a strategic partnership with Pharmefex Consulting (搜索) to integrate IND drafting and CMC support into its ModularCMC (搜索) platform.
The collaboration enhances Wheeler's platform by adding high-quality Common Technical Document Module 3 documentation preparation for IND submissions supporting First-in-Human clinical trials.
Wheeler Bio (搜索)'s scientific team brings aggregate industry experience working on over 1,400 unique molecules, while Pharmefex contributes decades of combined experience in CMC strategy and regulatory submissions.
Wheeler Bio (搜索), Inc., a U.S.-based contract development and biomanufacturing organization (CDMO), announced on September 9, 2025, the establishment of a strategic partnership with Pharmefex Consulting (搜索) to integrate Investigational New Drug (IND) drafting and Chemistry, Manufacturing, and Controls (CMC) support into Wheeler's ModularCMC (搜索)™ platform. The collaboration focuses on accelerating client success in IND filings and regulatory submissions for biologics development.
Enhanced Platform Capabilities
The partnership enhances Wheeler's ModularCMC (搜索) platform by integrating the preparation of high-quality Common Technical Document (CTD) Module 3 documentation in support of IND submissions for programs advancing from discovery to IND-enabled First-in-Human clinical trials. This integration adds Pharmefex's proven biologics regulatory expertise to Wheeler's streamlined and agile manufacturing platform, providing biopharmaceutical innovators with a comprehensive CMC offering that includes sound and defensible regulatory strategy.
Wheeler Bio (搜索) operates as a High-Science/High-Touch biologics CDMO, with a scientific team possessing aggregate industry experience that includes working on over 1,400 unique molecules. The ModularCMC (搜索) platform is designed to streamline the path from discovery to clinical study initiation with maximum speed, agility, and scalability while maintaining a High-Touch approach based on timely transparency, scientific rigor, and a true partnering mindset.
Strategic Value for Biopharmaceutical Innovation
"Biopharmaceutical innovators are seeking platform approaches that enable rapid progression of their innovative molecules," said Patrick Lucy (搜索), President and CEO of Wheeler Bio (搜索). "Adding Pharmefex's deep regulatory capabilities to our ModularCMC (搜索) platform lives up to that mandate."
Pharmefex Consulting (搜索) brings decades of combined experience across CMC strategy, regulatory submissions, and technical operations for biologics, biosimilars, and advanced therapies. The Pharmefex team, led by Ali Siahpush (搜索) Ph.D., president and founder of Pharmefex Consulting, will collaborate closely with Wheeler Bio (搜索)'s scientific, manufacturing, and quality teams to streamline the preparation and review of IND-enabling documentation including risk assessments, analytical methods, and process development reports.
Comprehensive Service Integration
The collaboration ensures that clients receive best-in-class regulatory support through the integration of both companies' expertise. Ali Siahpush (搜索) emphasized the strategic advantage this partnership offers: "We continuously seek innovative solutions which offer a strategic advantage to our clients as they endeavor to rapidly and efficiently advance their programs. We believe Wheeler Bio (搜索)'s ModularCMC (搜索) platform offers such an advantage. This is why we are proud to partner with Wheeler Bio."
Wheeler Bio (搜索)'s ModularCMC (搜索) platform enables the rapid translation of antibody-based therapeutics from discovery to clinical studies while ensuring scalability in support of advanced development and commercialization. The platform streamlines the path between drug discovery and clinical manufacturing through well-defined systematic work packages, ultimately resulting in cGMP product supported by comprehensive CTD Module 3 documentation for IND applications.
Company Backgrounds
Founded in 2014, Pharmefex specializes in CMC as a core competency, covering all aspects from process and analytical development to cGMP manufacturing, technology transfer, risk management, characterization, outsourcing and supply chain, as well as quality and regulatory affairs. The company's mission focuses on improving patient outcomes by increasing the success rates of innovative companies bringing new treatments to market while minimizing CMC timelines and reducing costs.
Wheeler Bio (搜索)'s mission centers on accelerating the translation of drug discoveries into clinical impact for partners and the patients they seek to serve, combining cutting-edge development and cGMP manufacturing technologies with a deeply experienced scientific team committed to timeline transparency, scientific rigor, and a true partnering mindset.